blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3199182

EP3199182 - COMPOSITION FOR PREVENTING OR TREATING PERIPHERAL ARTERY DISEASE USING HEPATOCYTE GROWTH FACTOR AND STROMAL CELL DERIVED FACTOR 1A [Right-click to bookmark this link]
Former [2017/31]COMPOSITION FOR PREVENTING OR TREATING PERIPHERAL VASCULAR DISEASE USING HEPATOCYTE GROWTH FACTOR AND STROMAL CELL DERIVED FACTOR 1
[2017/37]
StatusNo opposition filed within time limit
Status updated on  11.06.2021
Database last updated on 22.08.2024
FormerThe patent has been granted
Status updated on  03.07.2020
FormerGrant of patent is intended
Status updated on  11.06.2020
FormerExamination is in progress
Status updated on  26.05.2020
FormerGrant of patent is intended
Status updated on  17.04.2020
FormerExamination is in progress
Status updated on  02.10.2019
FormerRequest for examination was made
Status updated on  04.07.2017
FormerThe international publication has been made
Status updated on  11.04.2017
Most recent event   Tooltip08.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 10.08.2022  [2022/32]
Applicant(s)For all designated states
Helixmith Co., Ltd
203dong, 1, Gwanak-ro
Gwanak-gu, Seoul 08826 / KR
[2019/25]
Former [2017/31]For all designated states
Viromed Co., Ltd.
203dong Institute of Basic Science Bldg.
College of Natural Science
Seoul National University
Gwanak-ro 1, Gwanak-gu
Seoul 08826 / KR
Inventor(s)01 / JEONG, Jae-Gyun
102-402 Samsung Apt.
9 Yeongdeungpo-ro 3-gil
Yeongdeungpo-gu
Seoul 07276 / KR
02 / LEE, Jung Hun
108-1704 Heukseok Hangang Centreville Apt.
12 Heukseokhangang-ro
Dongjak-gu
Seoul 06981 / KR
03 / LEE, Nayeon
Suite 208 46 Gwanak-ro 14-gil
Gwanak-gu
Seoul 08788 / KR
 [2017/31]
Representative(s)J A Kemp LLP
80 Turnmill Street
London EC1M 5QU / GB
[N/P]
Former [2020/32]J A Kemp LLP
14 South Square
Gray's Inn
London WC1R 5JJ / GB
Former [2017/31]advotec.
Patent- und Rechtsanwälte
Widenmayerstrasse 4
80538 München / DE
Application number, filing date15843739.225.09.2015
[2017/31]
WO2015KR10240
Priority number, dateKR2014012936126.09.2014         Original published format: KR 20140129361
[2017/31]
Filing languageKO
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2016048105
Date:31.03.2016
Language:KO
[2016/13]
Type: A1 Application with search report 
No.:EP3199182
Date:02.08.2017
Language:EN
[2017/31]
Type: B1 Patent specification 
No.:EP3199182
Date:05.08.2020
Language:EN
[2020/32]
Search report(s)International search report - published on:KR31.03.2016
(Supplementary) European search report - dispatched on:EP29.03.2018
ClassificationIPC:A61K48/00, A61K38/18, A61P9/10, A61P9/00
[2017/31]
CPC:
A61K38/195 (EP,US); A61K38/18 (EP,CN,US); A61K38/1833 (EP,US);
A61K48/00 (EP,CN,US); A61K48/0016 (US); A61P9/00 (EP);
A61P9/10 (EP) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/31]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
TitleGerman:ZUSAMMENSETZUNG ZUR PRÄVENTION ODER BEHANDLUNG VON PERIPHERER GEFÄSSERKRANKUNG UNTER VERWENDUNG DES HEPATOZYTENWACHSTUMSFAKTORS UND FAKTORS 1A AUS STROMAZELLEN[2017/37]
English:COMPOSITION FOR PREVENTING OR TREATING PERIPHERAL ARTERY DISEASE USING HEPATOCYTE GROWTH FACTOR AND STROMAL CELL DERIVED FACTOR 1A[2020/28]
French:COMPOSITION POUR LA PRÉVENTION OU LE TRAITEMENT DES MALADIES VASCULAIRES PÉRIPHÉRIQUES UTILISANT LE FACTEUR DE CROISSANCE DES HÉPATOCYTES ET LE FACTEUR 1A DÉRIVÉ DES CELLULES STROMALES[2017/37]
Former [2017/31]ZUSAMMENSETZUNG ZUR PRÄVENTION ODER BEHANDLUNG VON PERIPHERER GEFÄSSERKRANKUNG UNTER VERWENDUNG DES HEPATOZYTENWACHSTUMSFAKTORS UND FAKTORS 1 AUS STROMAZELLEN
Former [2017/31]COMPOSITION FOR PREVENTING OR TREATING PERIPHERAL VASCULAR DISEASE USING HEPATOCYTE GROWTH FACTOR AND STROMAL CELL DERIVED FACTOR 1
Former [2017/31]COMPOSITION POUR LA PRÉVENTION OU LE TRAITEMENT DES MALADIES VASCULAIRES PÉRIPHÉRIQUES UTILISANT LE FACTEUR DE CROISSANCE DES HÉPATOCYTES ET LE FACTEUR 1 DÉRIVÉ DES CELLULES STROMALES
Entry into regional phase11.04.2017Translation filed 
11.04.2017National basic fee paid 
11.04.2017Search fee paid 
11.04.2017Designation fee(s) paid 
11.04.2017Examination fee paid 
Examination procedure11.04.2017Examination requested  [2017/31]
11.04.2017Date on which the examining division has become responsible
25.10.2018Amendment by applicant (claims and/or description)
08.10.2019Despatch of a communication from the examining division (Time limit: M04)
10.01.2020Reply to a communication from the examining division
24.04.2020Communication of intention to grant the patent
22.05.2020Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
12.06.2020Communication of intention to grant the patent
23.06.2020Fee for grant paid
23.06.2020Fee for publishing/printing paid
23.06.2020Receipt of the translation of the claim(s)
Opposition(s)07.05.2021No opposition filed within time limit [2021/28]
Fees paidRenewal fee
26.09.2017Renewal fee patent year 03
25.09.2018Renewal fee patent year 04
13.09.2019Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU25.09.2015
AL05.08.2020
AT05.08.2020
CY05.08.2020
CZ05.08.2020
DK05.08.2020
EE05.08.2020
FI05.08.2020
HR05.08.2020
LT05.08.2020
LV05.08.2020
MC05.08.2020
MK05.08.2020
MT05.08.2020
NL05.08.2020
PL05.08.2020
RO05.08.2020
RS05.08.2020
SE05.08.2020
SI05.08.2020
SK05.08.2020
SM05.08.2020
TR05.08.2020
IE25.09.2020
LU25.09.2020
BE30.09.2020
CH30.09.2020
LI30.09.2020
BG05.11.2020
NO05.11.2020
GR06.11.2020
IS05.12.2020
PT07.12.2020
[2022/32]
Former [2022/27]HU25.09.2015
AL05.08.2020
AT05.08.2020
CY05.08.2020
CZ05.08.2020
DK05.08.2020
EE05.08.2020
FI05.08.2020
HR05.08.2020
LT05.08.2020
LV05.08.2020
MC05.08.2020
MT05.08.2020
NL05.08.2020
PL05.08.2020
RO05.08.2020
RS05.08.2020
SE05.08.2020
SI05.08.2020
SK05.08.2020
SM05.08.2020
TR05.08.2020
IE25.09.2020
LU25.09.2020
BE30.09.2020
CH30.09.2020
LI30.09.2020
BG05.11.2020
NO05.11.2020
GR06.11.2020
IS05.12.2020
PT07.12.2020
Former [2021/37]AL05.08.2020
AT05.08.2020
CZ05.08.2020
DK05.08.2020
EE05.08.2020
FI05.08.2020
HR05.08.2020
LT05.08.2020
LV05.08.2020
MC05.08.2020
NL05.08.2020
PL05.08.2020
RO05.08.2020
RS05.08.2020
SE05.08.2020
SI05.08.2020
SK05.08.2020
SM05.08.2020
IE25.09.2020
LU25.09.2020
BE30.09.2020
CH30.09.2020
LI30.09.2020
BG05.11.2020
NO05.11.2020
GR06.11.2020
IS05.12.2020
PT07.12.2020
Former [2021/36]AL05.08.2020
AT05.08.2020
CZ05.08.2020
DK05.08.2020
EE05.08.2020
FI05.08.2020
HR05.08.2020
LT05.08.2020
LV05.08.2020
MC05.08.2020
NL05.08.2020
PL05.08.2020
RO05.08.2020
RS05.08.2020
SE05.08.2020
SI05.08.2020
SK05.08.2020
SM05.08.2020
LU25.09.2020
BE30.09.2020
BG05.11.2020
NO05.11.2020
GR06.11.2020
IS05.12.2020
PT07.12.2020
Former [2021/28]AL05.08.2020
AT05.08.2020
CZ05.08.2020
DK05.08.2020
EE05.08.2020
FI05.08.2020
HR05.08.2020
LT05.08.2020
LV05.08.2020
MC05.08.2020
NL05.08.2020
PL05.08.2020
RO05.08.2020
RS05.08.2020
SE05.08.2020
SK05.08.2020
SM05.08.2020
LU25.09.2020
BG05.11.2020
NO05.11.2020
GR06.11.2020
IS05.12.2020
PT07.12.2020
Former [2021/27]AL05.08.2020
AT05.08.2020
CZ05.08.2020
DK05.08.2020
EE05.08.2020
FI05.08.2020
HR05.08.2020
LT05.08.2020
LV05.08.2020
MC05.08.2020
NL05.08.2020
PL05.08.2020
RO05.08.2020
RS05.08.2020
SE05.08.2020
SM05.08.2020
LU25.09.2020
BG05.11.2020
NO05.11.2020
GR06.11.2020
IS05.12.2020
PT07.12.2020
Former [2021/25]AL05.08.2020
AT05.08.2020
CZ05.08.2020
DK05.08.2020
EE05.08.2020
FI05.08.2020
HR05.08.2020
LT05.08.2020
LV05.08.2020
NL05.08.2020
PL05.08.2020
RO05.08.2020
RS05.08.2020
SE05.08.2020
SM05.08.2020
BG05.11.2020
NO05.11.2020
GR06.11.2020
IS05.12.2020
PT07.12.2020
Former [2021/22]AT05.08.2020
CZ05.08.2020
DK05.08.2020
EE05.08.2020
FI05.08.2020
HR05.08.2020
LT05.08.2020
LV05.08.2020
NL05.08.2020
PL05.08.2020
RO05.08.2020
RS05.08.2020
SE05.08.2020
SM05.08.2020
BG05.11.2020
NO05.11.2020
GR06.11.2020
IS05.12.2020
PT07.12.2020
Former [2021/21]AT05.08.2020
DK05.08.2020
FI05.08.2020
HR05.08.2020
LT05.08.2020
LV05.08.2020
NL05.08.2020
PL05.08.2020
RS05.08.2020
SE05.08.2020
BG05.11.2020
NO05.11.2020
GR06.11.2020
IS05.12.2020
PT07.12.2020
Former [2021/12]AT05.08.2020
FI05.08.2020
HR05.08.2020
LT05.08.2020
LV05.08.2020
NL05.08.2020
PL05.08.2020
RS05.08.2020
SE05.08.2020
BG05.11.2020
NO05.11.2020
GR06.11.2020
IS05.12.2020
PT07.12.2020
Former [2021/10]AT05.08.2020
FI05.08.2020
HR05.08.2020
LT05.08.2020
LV05.08.2020
PL05.08.2020
RS05.08.2020
SE05.08.2020
BG05.11.2020
NO05.11.2020
GR06.11.2020
IS05.12.2020
PT07.12.2020
Former [2021/09]AT05.08.2020
FI05.08.2020
LT05.08.2020
SE05.08.2020
BG05.11.2020
NO05.11.2020
GR06.11.2020
PT07.12.2020
Former [2021/08]FI05.08.2020
LT05.08.2020
SE05.08.2020
BG05.11.2020
NO05.11.2020
PT07.12.2020
Former [2021/07]FI05.08.2020
LT05.08.2020
NO05.11.2020
Documents cited:Search[Y]WO2012027170  (PROVASCULON INC [US], et al) [Y] 1-14*cf. abstract, page 18, last para. bridging with first para. at page 19, furthermore claims 1 and 11*;
 [Y]WO2012170495  (PROVASCULON INC [US], et al) [Y] 1-14 *cf. abstract, page 1, lines 9-19, page 17, lines 11-16, claims 1 and 11*;
 [Y]US2013095060  (HSIEH PATRICK C H [TW], et al) [Y] 1-14 *cf. claims 1 and 11*;
 [X]  - MAJKA M ET AL, "SDF-1 alone and in co-operation with HGF regulates biology of human cervical carcinoma cells", FOLIA HISTOCHEMICA ET CYTOBIOLOGICA 2006 POLISH HISTOCHEMICAL AND CYTOCHEMICAL SOCIETY POL, (2006), vol. 44, no. 3, ISSN 0239-8508, pages 155 - 164, XP009504281 [X] 1-13 *cf. abstract and introductive part at pages 155/156*

DOI:   http://dx.doi.org/10.5603/4562
 [Y]  - MUROHARA ET AL, "Autologous adipose tissue as a new source of progenitor cells for therapeutic angiogenesis", JOURNAL OF CARDIOLOGY, NIHON SHINZOBYO GAKKAI, TOKYO, JP, vol. 53, no. 2, doi:10.1016/J.JJCC.2009.01.003, ISSN 0914-5087, (20090401), pages 155 - 163, (20090210), XP026014228 [Y] 1-13 *cf. summary, page 156, left col. 2nd para.*

DOI:   http://dx.doi.org/10.1016/j.jjcc.2009.01.003
International search[Y]WO03078568  (VIROMED CO LTD [KR], et al) [Y] 1-13 * See abstract; page 7, lines 4-6; claims 1-8; examples 1, 4; and sequence number 20. *;
 [Y]WO2008121719  (CLEVELAND CLINIC FOUNDATION [US], et al) [Y] 1-13 * See abstract; paragraphs [0006], [0040], [0073], [0090]; and claims 1-8. *;
 [Y]US7473425  (FUKUDA KEIICHI [JP], et al) [Y] 1-13 * See abstract; and table 1. *;
 [A]WO2012025925  (RAPPAPORT FAMILY INST FOR RES [IL], et al) [A] 1-13* See abstract; and claims 1-24. *;
 [Y]US8435953  (TABATA YASUHIKO [JP]) [Y] 1-13 * See abstract; column 14; claims 1-14, 18; and example 4. *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.